Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

December 16, 2010 — Treatment with zoledronic acid (Zometa) appears to have benefits beyond bone health in patients with multiple myeloma. Researchers in the United Kingdom report that overall ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Zoledronic acid administration during the initial hospitalization for osteoporotic hip fracture significantly reduces all-cause mortality and subsequent vertebral fractures among older patients.

FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer Women with bone metastases (N = 228) were randomly assigned to ...

September 26, 2011 (Stockholm, Sweden) — Further analysis of a subgroup from the large AZURE trial shows that when zoledronic acid (Zometa) was added to chemotherapy in postmenopausal women with ...

(HealthDay)—Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although ...